Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Diverse Diversity

The Diverse Diversity EDITORIAL Tony S. K. Mok, MD, and Kwok Chi Lam, MBBS he human being is genomically similar to a chimpanzee, while phenotypically 1,2 Tdifferent. Most of the differences are due to a relatively small number of changes in gene regulation, implying that small genomic differences may cause significant pheno- typic diversities. Simple base-pair deletion at epidermal growth factor receptor (EGFR) exon 19 or single point mutation at EGFR exon 21 has dramatically shifted the treatment paradigm of patients with advanced non-small cell lung cancer. Most patients with the mutation will likely respond to EGFR tyrosine kinase inhibitor (TKI) such as gefitinib or 3–5 erlotinib and benefit from a prolonged duration of progression-free survival. EGFR TKI is now considered a standard first-line therapy for patients harboring the EGFR mutation. The key issue is to identify these patients in daily practice, thus population-based incidence rate will be an important guide to oncologists. Helland et al. reported in the current issue of Journal of Thoracic Oncology the EGFR mutation rate of 7.5% in Norwegian patients with resectable early-stage non-small cell lung cancer. This represents the first report from northern Europe. Authors chose to study the incidence on resected lung tumor to reduce http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

The Diverse Diversity

Lam, Kwok Chi
Journal of Thoracic Oncology , Volume 6 (5) – May 1, 2011
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/the-diverse-diversity-Ygj0jrWTyX

References (14)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31821972ed
pmid
21623264
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Tony S. K. Mok, MD, and Kwok Chi Lam, MBBS he human being is genomically similar to a chimpanzee, while phenotypically 1,2 Tdifferent. Most of the differences are due to a relatively small number of changes in gene regulation, implying that small genomic differences may cause significant pheno- typic diversities. Simple base-pair deletion at epidermal growth factor receptor (EGFR) exon 19 or single point mutation at EGFR exon 21 has dramatically shifted the treatment paradigm of patients with advanced non-small cell lung cancer. Most patients with the mutation will likely respond to EGFR tyrosine kinase inhibitor (TKI) such as gefitinib or 3–5 erlotinib and benefit from a prolonged duration of progression-free survival. EGFR TKI is now considered a standard first-line therapy for patients harboring the EGFR mutation. The key issue is to identify these patients in daily practice, thus population-based incidence rate will be an important guide to oncologists. Helland et al. reported in the current issue of Journal of Thoracic Oncology the EGFR mutation rate of 7.5% in Norwegian patients with resectable early-stage non-small cell lung cancer. This represents the first report from northern Europe. Authors chose to study the incidence on resected lung tumor to reduce

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: May 1, 2011

There are no references for this article.